1. Executive Summary
In recent years, there has been renewed interest in PRED-455, driven in part by the growing need for effective and safe treatments for anxiety disorders. A 2019 review published in the Journal of Clinical Psychopharmacology highlighted the potential benefits of PRED-455 as a novel anxiolytic agent, citing its unique mechanism of action and promising preclinical and clinical data. PRED-455
Research on PRED-455 is ongoing, with several studies investigating its biological activities and potential therapeutic applications. While the compound shows promise, further research is needed to fully understand its mechanisms of action, efficacy, and safety. Research on PRED-455 is ongoing, with several studies
: Data points from preclinical assays used to extract knowledge for drug discovery. ResearchGate is calculated or its specific clinical thresholds As a result
PRED-455 acts as a potent and selective agonist at the 5-HT1A receptor, a subtype of the serotonin receptor. By activating this receptor, PRED-455 increases the release of neurotransmitters, such as dopamine, norepinephrine, and serotonin, which are involved in regulating mood, anxiety, and cognitive function. This mechanism is distinct from that of benzodiazepines, which enhance the activity of GABA, an inhibitory neurotransmitter. As a result, PRED-455 is expected to produce anxiolytic effects without the sedative and dependence liabilities associated with benzodiazepines.